Select tickets
We’re excited to return to Hyderabad for the Lhasa India Symposium 2026
Designed for scientists, toxicologists, regulatory professionals, quality teams and pharmaceutical development specialists, this one-day symposium will explore how exposure-based decision-making can support confident, scientifically justified safety assessments across pharmaceutical development and regulatory submission workflows.
The programme brings together Lhasa experts, industry speakers and regulatory perspectives to discuss key challenges across extractables and leachables, ICH Q3E, degradation, forced degradation studies, impurity qualification, purge, ICH M7, genetic toxicology and curated decision-support data.
Why attend?
Pharmaceutical safety decisions rarely sit in isolation. Early quality and formulation decisions can influence downstream impurity assessment, toxicological evaluation, regulatory strategy and the evidence needed to defend control approaches.
This symposium will help attendees explore how in silico science, expert review, read-across, curated data and practical risk assessment workflows can support clearer, more consistent decision-making.
Across the day, attendees will gain practical insight into:
- Extractables and leachables risk assessment, including evolving expectations linked to ICH Q3E
- Multifaceted read-across approaches for E&L assessment and surrogate selection
- Degradation prediction and forced degradation study considerations
- Impurity qualification challenges in regulatory submissions
- Purge and exposure evaluation as part of ICH M7 risk assessment
- Mutagenic impurity classification and genetic toxicology decision support
- The role of curated data in point of departure selection, expert review and safety justification
A connected risk assessment workflow
The programme has been designed to show how individual scientific decisions connect across a wider pharmaceutical risk assessment workflow.
Sessions will explore how Lhasa in silico solutions and scientific expertise can support practical challenges, from early degradation prediction and E&L assessment through to mutagenicity classification, purge evaluation and genetic toxicology decision support. Through expert presentations, case-based discussion and interactive sessions, attendees will leave with practical takeaways they can apply to their own impurity assessment, safety evaluation and regulatory submission workflows.
Through expert presentations, case-based discussion and interactive sessions, attendees will leave with practical takeaways they can apply to their own impurity assessment, safety evaluation and regulatory submission workflows.
Who should attend?
- Toxicologists and safety scientists
- Regulatory affairs professionals
- Quality, CMC and pharmaceutical development teams
- Scientists working in impurity assessment, degradation, E&L, purge or ICH M7 workflows
- Teams responsible for building, reviewing or defending chemical safety decisions